Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
561-580 of 847 trials

Lung Cancer Treatment: Nivolumab + Relatlimab with Chemotherapy

We are studying if a new combination treatment helps people with advanced non-small cell lung cancer live longer compared to standard treatment. This trial is for those whose cancer has spread or returned after previous treatment.

Advanced Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

IDH1/IDH2-Mutant Glioma: Vorasidenib with Temozolomide

We are studying the safety and effectiveness of a new drug, vorasidenib, combined with temozolomide for patients with IDH1- or IDH2-mutant gliomas. This research aims to see if this combination can improve treatment outcomes.

IDH1-mutant GliomaIDH2-mutant Glioma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Cystic Fibrosis: VX-121/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for children with cystic fibrosis to evaluate its safety and how well it works. This trial focuses on kids aged 1 to 11 years.

Cystic Fibrosis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Rare Cancers: Targeted Drug Study

We are exploring how well existing targeted cancer drugs work for patients with rare and hard-to-treat cancers. The study will also look at any serious side effects from these treatments.

Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Alzheimer's Agitation: Masupirdine Study

We are investigating whether masupirdine can help reduce agitation symptoms in people with Alzheimer's. The study will compare its effects to a placebo over 12 weeks.

Alzheimer's Disease3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Colorectal Cancer: Amivantamab with Chemotherapy

We are comparing a new treatment combining Amivantamab and chemotherapy to Cetuximab with chemotherapy for patients with certain types of colorectal cancer. This study aims to find out which option may help patients live longer without their cancer worsening.

Left-sided Colorectal CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Efgartigimod for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will evaluate the safety, dosing, and effects of this treatment on their daily lives.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Achondroplasia: Long-Term Study of Infigratinib

We are studying the long-term safety and effects of Infigratinib in children with Achondroplasia. The goal is to see how it impacts their growth and overall health.

Achondroplasia>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOrthopedics and TraumatologyPediatrics

Opioid Dependency Treatment: Suboxone vs. Methadone

We are comparing the effectiveness of Suboxone and methadone in reducing opioid misuse for patients with chronic pain. The study also looks at how these treatments affect pain relief, well-being, and cognitive function.

Opioid Use Disorder>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePsychiatry

Advanced Breast Cancer: Capivasertib and Fulvestrant Study

We are researching the combination of capivasertib and fulvestrant for patients with HR+/HER2- advanced breast cancer who have not responded to standard treatments. The study aims to evaluate treatment effectiveness and safety in real-world clinical practice.

Advanced Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

TBR1-Related Neurocognitive Disorder: Lithium Carbonate Study

We are studying whether lithium carbonate can improve behavior and communication in patients with TBR1-related neurocognitive disorder. This trial will also assess the treatment's safety and overall impact on quality of life.

TBR1 Variant>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteNeurologyPsychiatry

HPV Infections: 2LPAPI® Treatment Study

We are testing a new treatment, 2LPAPI®, for people with high-risk HPV infections to see if it helps clear the virus better than a placebo. The study also looks at safety and how the treatment affects cervical cell health.

Human Papillomavirus Infection>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesGynecology and ObstetricsInfectious Diseases

Sickle Cell Disease: CTX001 Treatment for Kids

We are studying a new gene-editing treatment for children with severe sickle cell disease. The trial aims to evaluate its safety and effectiveness in improving their health.

Sickle Cell Anaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics

Papillary Renal Cell Carcinoma: Axitinib with or without Pembrolizumab

We are studying the effects of axitinib alone versus axitinib combined with pembrolizumab in patients with advanced papillary renal cell carcinoma. This research aims to find out which treatment may work better as a first-line option.

Metastatic Renal Cell CarcinomaLocally Advanced or Metastatic Papillary Cell Carcinoma3-6 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyUrology

Pulmonary Hypertension: Mosliciguat Study

We are testing the medication Mosliciguat for individuals with pulmonary hypertension related to interstitial lung disease. The study aims to see if it helps improve heart function and walking ability.

Pulmonary Hypertension6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Lung Cancer Treatment: CT-P51 vs. Keytruda

We are comparing the effects and safety of CT-P51 and Keytruda in patients with untreated metastatic lung cancer. This study aims to find out if CT-P51 works as well as Keytruda when combined with chemotherapy.

Previously Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Acute Myeloid Leukemia: Molidustat and Ivosidenib Combination

We are investigating whether the combination of molidustat and ivosidenib can effectively treat patients with IDH1-mutated acute myeloid leukemia or myelodysplastic syndrome. This study aims to assess how well this treatment works and its safety.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Sacituzumab Govitecan with Bevacizumab for Brain Metastases in Lung Cancer

We are studying a combination of two medications for patients with brain metastases from non-small cell lung cancer. The goal is to see how well this treatment works in reducing tumor size and improving patient outcomes.

Lung Cancer6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOncology

PD-1 Antibody for Metastatic Solid Tumors

We are testing a new method of delivering a PD-1 antibody directly into the spinal fluid for patients with metastatic solid tumors and leptomeningeal disease. The study aims to determine the safe dosage and its potential impact on survival.

Leptomeningeal Disease6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyOncology

Atrial Fibrillation: Amiodarone Dose Comparison

We are studying whether a standard or reduced dose of amiodarone is more effective in keeping a normal heart rhythm after cardioversion in patients with persistent atrial fibrillation. We will also assess any side effects and how genetics may affect treatment.

Persistent Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCardiologyInternal Medicine